
BINOL-Linked 1,2,3-Triazoles: An Unexpected Fluorescent Sensor with Anion- π Interaction for Iodide Ion

Cai-Yun Wang,^{†*a*} Jin-Feng Zou,^{†*a*} Zhan-Jiang Zheng,^{**a*} Wei-Sheng Huang^{*a*}, Li Li,^{*a*} and Li-Wen Xu^{**a,b*}

[a] Key Laboratory of Organosilicon Chemistry and Material Technology of Ministry of Education, and College of Material, Chemistry and Chemical Engineering, Hangzhou Normal University, Hangzhou 310012, P. R. China. Fax: 86 2886 5135; Tel: 86 2886 5135; E-mail: zzjiang78@hotmail.com and liwenxu@hznu.edu.cn

[b] State Key Laboratory for Oxo Synthesis and Selective Oxidation, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou, 730000, P. R. China; E-mail: licpxulw@yahoo.com


† J. F. Zou and C. Y. Wang contributed equally to this work.

Table of Contents

1. General information for synthesis and characterization of compound 1-6	1
2. Fluorescence emission spectra of Ligand 2 in CH ₃ CN in the presence of various anions.....	7
3. Fluorescence spectra of Ligand 2-6 in CH ₃ CN with increasing concentration of I ⁻	8
4. UV-Vis titration spectra of Ligand 2-6 in CH ₃ CN with increasing concentration of I ⁻ in CH ₃ CN.....	12
5. ¹ HNMR spectrum (500 MHz, CDCl ₃) of Ligand 1-5 before and after addition of 10 equiv of I ⁻	15
6. ¹ H-NMR and ¹³ C-NMR spectra of the new compounds.....	20

1. General information for synthesis and characterization of compound 1-6

All reagents were used as purchased. Substituted azides were synthesised at room temperature from the corresponding bromides with sodium azide in DMF^{2,3}, Amino-functional Polysiloxane (AFP) was purchased from Hangzhou Bald Silicone Co., Ltd. (0.55 mmol /g polysiloxane, Mw ~1900). Flash column chromatography was performed over silica (100-200 mesh). ¹H-NMR and ¹³C-NMR spectra were recorded at 400 and 100 MHz, respectively on Advance (Bruker) 400 MHz Nuuclear Magnetic Resonance Spectrometer, and were referenced to the internal solvent signals. GC-MS was performed on TRACE DSQ. High Resolution Mass Spectra (ESI-HRMS) were operated on a microOTOF-Q II (Bruker). IR spectra were recorded using a FTIR apparatus (Nicolot 5700). UV/Vis spectra were recorded on a Shimadzu UV-2550 spectrophotometer. Fluorescence spectra were measured on a Hitachi F-2700 FL spectrophotometer with a xenon arc lamp as light source. Thin layer chromatography was performed using Silica.




Scheme S1 Synthetic approach to compound **1** and **4**

*Synthesis of compound **1** and **4**.* Amine-functional polysiloxane **AFP** (0.1 mmol) and CuCl (0.05 mmol) was added into a solution of azide (1.0 mmol) and dipropargyl compound (1.0 mmol) in CH_2Cl_2 (4 mL). The resulting mixture was stirred at 0°C for

24h and diluted with MeOH (10 mL), then the solution was passed through a short pad of Celite. The filtrate was dried (Na_2SO_4), concentrated in vacuo, and purified by column chromatograph on silica gel to gain the desired cyclic compound **1** and **4**.

Ligand **1** was obtained as a white solid in 35% yield. $^1\text{H-NMR}$ (CDCl_3 , 400MHz), $\delta = 7.81$ (m, Naph-H, 4H), 7.49 (m, Naph-H, 2H), 7.38 (m, Naph-H, 5H), 7.24 (m, Naph-H, 1H), 7.09 (m, Ph-H, 2H), 6.90 (m, Ph-H, 6H), 6.84(d, $J = 8.4\text{Hz}$, Ph-H, 2H), 5.28 (d, $J = 14.8\text{ Hz}$, O- CH_2 , 2H), 4.85 (d, $J = 10.8\text{ Hz}$, Ph- CH_2 , 2H), 4.57 (d, $J = 14.8\text{ Hz}$, O- CH_2 , 2H), 3.64 (d, $J = 10.8\text{ Hz}$, Ph- CH_2 , 2H). $^{13}\text{C-NMR}$ (CDCl_3 , 100MHz), $\delta = 171.3, 154.1, 146.9, 134.0, 133.8, 129.4, 129.3, 128.9, 128.1, 127.8, 126.3, 125.9, 123.5, 122.3, 118.0, 113.4, 60.6, 53.2$. HRMS calcd. for $\text{C}_{40}\text{H}_{30}\text{N}_6\text{NaO}_2$, 649.2322 [$\text{M}+\text{Na}$] $^+$, found 649.2347. IR(cm^{-1}), 3055, 2928, 2359, 2323, 1750, 1622, 1593, 1508, 1456, 1322, 1251, 1083, 1036, 1017, 915, 807, 750, 714.

Ligand **4** was obtained as a white solid in 28% yield. $^1\text{H-NMR}$ (CDCl_3 , 400MHz), $\delta = 7.89$ (d, $J = 9.2\text{ Hz}$, Naph-H, 2H), 7.83 (d, $J = 8.0\text{ Hz}$, Naph-H, 2H), 7.37 (d, $J = 9.2\text{ Hz}$, Naph-H, 2H), 7.28 (m, Naph-H, 2H), 7.09 (t, $J = 7.2\text{ Hz}$, Naph-H, 2H), 6.94 (d, $J = 8.8\text{ Hz}$, Naph-H, 2H), 5.29 (m, O- CH_2 , 2H), 4.88 (m, O- CH_2 and COOEt- CH_2 , 6H), 4.17 (m, O CH_2CH_3 , 4H), 1.22 (t, $J = 7.2\text{ Hz}$, O CH_2CH_3 , 6H). $^{13}\text{C-NMR}$ (CDCl_3 , 100MHz), $\delta = 166.2, 154.4, 146.5, 134.1, 129.6, 129.1, 127.9, 126.4, 125.9, 123.6, 123.5, 118.2, 114.1, 62.7, 61.5, 49.6, 14.0$. HRMS calcd. for $\text{C}_{34}\text{H}_{30}\text{N}_6\text{NaO}_6$, 641.2119 [$\text{M}+\text{Na}$] $^+$, found 641.2129. IR(cm^{-1}), 3062, 2928, 2854, 2365, 1749, 1624, 1594, 1508, 1458, 1376, 1323, 1229, 1147, 1081, 1017, 915, 806, 747, 667, 582.



Scheme S2 Synthetic approach to compound **2**, **3**, **5** and **6**.

Synthesis of compound X. The compound **X** was prepared according to reported method¹ in 92% yield. ¹H-NMR (CDCl₃, 400MHz), δ = 8.02 (d, J=8.8 Hz, Naph-H, 1H), 7.93 (m, Naph-H, 2H), 7.88 (d, J=8.4 Hz, Naph-H, 1H), 7.61 (d, J=8.8 Hz, Naph-H, 1H), 7.44 (d, J=8.8 Hz, Naph-H, 1H), 7.36 (m, Naph-H, 2H), 7.20 (m, Naph-H and Ph-H, 7H), 7.03 (m, Ph-H, 2H), 4.05-5.13 (AB-quartet, J=12.4 Hz, Ph-CH₂, 2H), 4.60 (dq, J=2.4 Hz, 16.4 Hz, O-CH₂, 2H), 2.36 (t, J=2 Hz, C≡CH, 1 H). ¹³C-NMR (CDCl₃, 100MHz), δ = 154.0, 153.2, 137.6, 134.1, 134.0, 129.8, 129.4, 129.3, 128.2, 127.9, 127.3, 126.8, 126.4, 126.3, 125.6, 125.5, 124.0, 123.8, 120.9, 120.3, 116.1, 115.8, 79.3, 76.7, 75.3, 71.2, 57.1. HRMS calcd. for C₃₀H₂₂NaO₂, 437.1512 [M+Na]⁺, found 437.1563. IR(cm⁻¹), 3282, 3057, 2924, 2868, 2363, 2120, 1733, 1621, 1591, 1507, 1453, 1431, 1354, 1328, 1271, 1218, 1146, 1087, 1048, 1017,

805, 746, 695, 637.

Synthesis of compound 2, 3, 5 and 6. NEt₃(0.1 mmol) and CuCl (0.05 mmol) was added into a solution of substituted azide (2.0 or 1.0 mmol) and the alkyne compound (1.0 mmol) in CH₂Cl₂ (4 mL). The resulting mixture was stirred at 25 °C for 24h, and then the solvent was removed in vacuo, and the crude product was further purified by column chromatograph on silica gel to give the desired cyclic compound **2, 3, 5** and **6**.

Ligand **2** was obtained as a white solid in 66% yield, ¹H-NMR (CDCl₃, 400MHz), δ = 7.86 (m, Naph-H, 4H), 7.43 (d, J=9.2 Hz, Naph-H, 2H), 7.33 (m, Ar-H, 8H), 7.14 (m, Ph-H, 4H), 7.07 (d, J=6.0 Hz, Ph-H, 4H), 6.42 (s, Triazole-H, 2H), 5.20 (s, O-CH₂, 4H), 5.15 (d, J=12.8 Hz, Ph-CH₂, 2H), 5.04 (d, J=12.8 Hz, Ph-CH₂, 2H). ¹³C-NMR (CDCl₃, 100MHz), δ = 153.6, 145.1, 134.6, 133.9, 129.4, 129.0, 128.6, 128.0, 127.9, 126.4, 125.4, 123.9, 122.4, 120.7, 115.9, 64.0, 53.9. HRMS calcd. for C₄₀H₃₃N₆O₂, 629.2660 [M+H]⁺, found 629.2676.. IR(cm⁻¹), 2067, 1625, 1591, 1507, 1458, 1433, 1356, 1329, 1260, 1241, 1208, 1148, 1117, 1087, 1046, 1016, 904, 814, 775, 755, 711, 695, 589.

Ligand **3** was obtained as a white solid in 82% yield, ¹H-NMR (CDCl₃, 400MHz), δ = 7.96 (d, J=9.2 Hz, Naph-H, 1H), 7.90 (d, J=8.0 Hz, Naph-H, 1H), 7.83 (t, J=9.2 Hz, Naph-H, 2H), 7.47 (d, J=9.2 Hz, Naph-H, 1H), 7.33(m, Naph-H, 6H), 7.23(m, Ar-H, 2H), 7.11(m, Ph-H, 5H), 7.00 (d, J=6.44 Hz, Ph-H, 2H), 6.87 (d, J=6.8 Hz, Ph-H, 2H), 6.43 (s, Triazole-H, 1H), 5.16 (m, O-CH₂, 4H), 4.91-4.98 (AB-quartet, J= 12.8 Hz, Ph-CH₂, 2H). ¹³C-NMR (CDCl₃, 100MHz), δ = 153.9, 153.5, 145.5, 137.3, 134.6, 134.0, 133.9, 129.5, 129.3, 129.2, 128.9, 128.6, 128.2, 128.0, 127.9, 127.8, 127.5, 126.8, 126.5, 126.4, 125.5, 125.4, 123.9, 123.8, 122.4, 120.7, 120.6, 116.0, 115.9, 71.2, 64.1, 53.8. HRMS calcd. for C₃₇H₃₀N₃O₂, 548.2333 [M+H]⁺, found 548.2347. IR(cm⁻¹), 3140, 3057, 3032, 2930, 2872, 2362, 1621, 1590, 1506, 1455, 1431, 1354, 1328, 1221, 1147, 1087, 1046, 1016, 904, 807, 747, 731, 695.

Ligand **5** was obtained as a white solid in 62% yield, ¹H-NMR (CDCl₃, 400MHz), δ = 7.96 (d, J= 8.8 Hz, Naph-H, 2H), 7.88 (d, J= 8.4 Hz, Naph-H, 2H), 7.53 (d, J= 8.8 Hz, Naph-H, 2H), 7.35 (t, J= 7.2 Hz, Naph-H, 2H), 7.22 (m, Naph-H, 2H),

7.15 (d, J= 8.4 Hz, Naph-H, 2H), 6.81 (s, Triazole-H, 2H), 5.27 (d, J= 13.2 Hz, O-CH₂, 2H), 5.14 (d, J= 13.2 Hz, O-CH₂, 2H), 4.90 (s, -CH₂COOEt, 4H), 4.21 (q, J= 7.2 Hz, OCH₂CH₃, 4H), 1.25 (t, J=6.8 Hz, OCH₂CH₃, 6H). ¹³C-NMR (CDCl₃, 100MHz), δ= 166.1, 153.6, 145.0, 134.0, 129.6, 129.5, 127.9, 126.5, 125.5, 124.1, 123.9, 120.7, 115.9, 63.8, 62.3, 50.7, 40.0. HRMS calcd. for C₃₄H₃₂N₆NaO₆, 643.2276 [M+Na]⁺, found 643.2276. IR(cm⁻¹), 3146, 3057, 2929, 2362, 2330, 1750, 1623, 1592, 1507, 1458, 1375, 1262, 1214, 1148, 1086, 1049, 1017, 809, 750.

Ligand **6** was obtained as a white solid in 78% yield, ¹H-NMR (CDCl₃, 400MHz), δ = 7.96 (d, J=8.8 Hz, Naph-H, 2H), 7.88 (m, Naph-H, 2H), 7.46 (d, J=8.8 Hz, Naph-H, 2H), 7.35 (m, Naph-H, 2H), 7.21(m, Naph-H, 4H), 7.11(m, Ph-H, 3H), 6.86 (d, J=7.2 Hz, Ph-H, 2H), 6.78 (s, Triazole-H, 1H), 5.30 (d, J=13.6 Hz, O-CH₂, 1H), 5.21 (d, J=13.6 Hz, O-CH₂, 1H), 5.07 (d, J=12.4 Hz, O-CH₂, 1H), 4.98 (d, J=12.4 Hz, O-CH₂, 1H), 4.68 (d, J=17.6 Hz, COOEt-CH₂, 1H), 4.50 (d, J=17.6 Hz, COOEt-CH₂, 1H), 4.17 (m, OCH₂CH₃, 2H), 1.23 (t, J=7.2 Hz, OCH₂CH₃, 3H). ¹³C-NMR (CDCl₃, 100MHz), δ= 165.9, 154.0, 153.3, 145.4, 137.3, 134.1, 134.0, 129.6, 129.5, 129.4, 129.3, 128.2, 128.0, 127.9, 127.5, 126.8, 126.5, 126.4, 125.5, 125.4, 124.0, 123.9, 123.8, 120.8, 120.6, 116.2, 115.7, 71.4, 63.6, 62.3 , 50.5, 40.1. HRMS calcd. for C₃₄H₃₀N₃O₄, 544.2231 [M+H]⁺, found 544.2257. IR(cm⁻¹), 3144, 3057, 2982, 2938, 2873, 2364, 1751, 1621, 1591, 1455, 1431, 1374, 1354, 1328, 1262, 1215, 1147, 1088, 1047, 1017, 905, 866, 807, 747, 696, 577.

Reference:

- 1) C. Efe, I. N. Lykakis, M. Stratakis, *Chem. Commun.*, 2011, **47**, 803.

2. Fluorescence emission spectra of Ligand 2 in CH₃CN in the presence of various anions.




Figure S1 Fluorescence emission spectra of Ligand 2 (6.3 μ M) in CH₃CN in the presence of various anions (100eq): F⁻, Cl⁻, Br⁻, I⁻, NO₃⁻, CH₃COO⁻, HSO₄⁻ and H₂PO₄⁻.

3. Fluorescence spectra of Ligand 2-6 (5 μ M) in CH₃CN with increasing concentration of I⁻




Figure S2 Fluorescence spectra of Ligand 2 (10 μ M) in CH₃CN with increasing concentration of I⁻, Inset shows a Modified Stern-Volmer plot of Ligand 2 upon the addition of I⁻ in CH₃CN.




Figure S3 Fluorescence spectra of Ligand **3** (5 μM) in CH_3CN with increasing concentration of Γ , Inset shows a Modified Stern-Volmer plot of Ligand **3** upon the addition of Γ in CH_3CN .




Figure S4 Fluorescence spectra of Ligand **4** (5 μM) in CH_3CN with increasing concentration of Γ , Inset shows a Modified Stern-Volmer plot of Ligand **4** upon the addition of Γ in CH_3CN .




Figure S5 Fluorescence spectra of Ligand **5** (5 μM) in CH_3CN with increasing concentration of Γ , Inset shows a Modified Stern-Volmer plot of Ligand **5** upon the addition of Γ in CH_3CN .




Figure S6 Fluorescence spectra of Ligand **6** (5 μ M) in CH_3CN with increasing concentration of Γ , Inset shows a Modified Stern-Volmer plot of Ligand **6** upon the addition of Γ in CH_3CN .

4. UV-Vis titration spectra of Ligand 2-6 (5 μ M) in CH₃CN with increasing concentration of I⁻ in CH₃CN




Figure S7 UV-Vis titration spectra of Ligand 2 (10 μ M) in CH₃CN with increasing concentration of I⁻ in CH₃CN.




Figure S8 UV-Vis titration spectra of Ligand **3** (5 μM) in CH_3CN with increasing concentration of I in CH_3CN .




Figure S9 UV-Vis titration spectra of Ligand **4** (5 μM) in CH_3CN with increasing concentration of I in CH_3CN .




Figure S10 UV-Vis titration spectra of Ligand **5** (5 μM) in CH_3CN with increasing concentration of I^- in CH_3CN .




Figure S11 UV-Vis titration spectra of Ligand **6** (5 μM) in CH_3CN with increasing concentration of I^- in CH_3CN .

5. ^1H NMR spectrum (500 MHz, CDCl_3) of Ligand 1-5 before and after addition of 10 equiv of I^- .




Figure S12 ^1H NMR spectrum (500 MHz, CDCl_3) of Ligand 1 before (a), (c) and after addition of 10 equiv of I^- (b), (d).




Figure S13 ^1H NMR spectrum (500 MHz, CDCl_3) of Ligand **2** before (a), (c) and after addition of 10 equiv of I^- (b), (d).




Figure S14 ^1H NMR spectrum (500 MHz, CDCl_3) of Ligand **3** before (a), (c) and after addition of 10 equiv of I^- (b), (d).




Figure S15 ^1H NMR spectrum (500 MHz, CDCl_3) of Ligand **4** before (a), (c) and after addition of 10 equiv of I^- (b), (d).




Figure S16 ^1H NMR spectrum (500 MHz, CDCl_3) of Ligand **5** before (a), (c) and after addition of 10 equiv of Γ (b), (d).

6. ^1H -NMR and ^{13}C -NMR spectra of the new compounds

